

Preparing for Future Efficacy Trials: Revisiting the Screening Test of Concept (STOC) Design for AIDS Vaccines

**Frances Priddy, MD MPH
International AIDS Vaccine Initiative
AIDS Vaccine 2008 Cape Town
October 14, 2008**

Background

- ▶ Multiple duplicative CMI vaccine candidates
- ▶ Correlate(s) of protection is not known
- ▶ Vaccines designed to elicit cellular immune response are not expected to prevent infection
- ▶ Vaccines that elicit effective humoral responses are years away
- ▶ High incidence cohorts are harder to identify

And...

- ▶ Trend towards harm seen in recent large trial of Ad5 vectored vaccines



Screening Test of Concept (STOC) Origins

Problem: How to rapidly select the CMI-based vaccine approaches worthy of advancement?

- ▶ UNAIDS/IAVI/WHO Consensus Mtg - Phase IIB TOC, February 2006
- *AIDS* 2007
- ▶ AIDS Vaccine Amsterdam, September 2006
- ▶ Excler, *AIDS* 2007
- ▶ UNAIDS Vaccine Advisory Committee, May 2008
- ▶ NIAID Summit on HIV Vaccine R&D, March 2008
- Consider smaller trial design instead of PAVE100A
- ▶ Enterprise Consultation, New York, April 2008



A Spectrum of Efficacy Trials

▶ HIV infections required to evaluate efficacy

| | |
|---------------|--|
| STOC | ~ 30 per protocol, ~ 40 mITT |
| Ph2B TOC | ~ 50 per protocol |
| PAVE 100A | ~ 60 weighted ITT |
| USMHRP-RV 144 | ~ 129 mITT |
| VaxGen 004 | ~ 200 mITT (design), ~368 mITT(actual) |

▶ Limitations of larger end of spectrum


- Resources
 - ▶ Time, money, high incidence cohorts
- Number of people at risk

STOC Design

- ▶ Screens CMI candidates for evidence of impact on disease progression or surrogates (VEp)
- ▶ Accepts greater uncertainty about vaccine effect on acquisition (VEs) to accelerate candidate selection; assumes VEs $\leq 30\%$
- ▶ Detects $\geq 1.0 \log_{10}$ reduction in VL at set point (1-sided, 0.05 alpha level test, power $\geq 80\%$)
- ▶ Requires 30 per protocol infections to have adequate statistical power
- ▶ Consider advancing candidate if $\geq 1.0 \log_{10}$ VL reduction observed

STOC Design

- ▶ Randomized 1:1, vaccine: placebo
 - Stratified by important predictors of HIV susceptibility
- ▶ Duration ~ 3 years
- ▶ HIV testing every 2 months
- ▶ Endpoint is 'set point' viral load
 - Geometric mean of VL at first 2 time points
- ▶ HIV infections followed in separate study




Example of STOC Sample Size to Achieve 30 Endpoints

| Annual HIV incidence | Minimum post-vaccination follow-up | | |
|----------------------|------------------------------------|-------|-------|
| | 12 mo | 18 mo | 24 mo |
| 2% | 1312 | 956 | 757 |
| 3% | 881 | 643 | 511 |
| 4% | 665 | 487 | 388 |
| 5% | 535 | 393 | 314 |
| 6% | 449 | 331 | 265 |
| 7% | 388 | 286 | 230 |

Assumptions:

- Enrollment period is 6 months
- 5% loss to follow-up rate during the 6 month vaccination period and a 5% annual loss to follow-up rate during the post vaccination follow-up
- Infections occurring during the vaccination period are excluded
- Protective vaccine effect on susceptibility is 0%

The Development Pathway



*Larger STOC, Phase IIB if needed to collect additional safety data and screen for efficacy in other populations

How well does STOC address:

- ▶ Harm
- ▶ Correlates of immunity
- ▶ Heterogeneity – host or viral



Monitoring for Harm – HIV Acquisition

- ▶ STOC is designed to screen for efficacy, not to rule-out harm
- ▶ However, STOC can rule-out ≥ 2.4 -fold increase in relative risk of HIV acquisition

Monitoring for Harm – HIV Acquisition

Minimum increase in RR of HIV acquisition ruled out with various study designs

| Design | Number of Events | RR | Power ¹ |
|---------------------------------|------------------|-------------|--------------------|
| STOC (interim) | 20-25 mITT | ≥ 3.6 | 80% |
| STOC | 40 mITT | ≥ 2.4 | 80% |
| PAVE100A | 60 wITT | ≥ 2.1 | 80% |
| Large safety trial ² | 509 | ≥ 1.33 | 90% |

¹ Power is 80%, one-sided 0.025 level test when true RR is 1.0

² Fleming, *NEJM* 2008

Monitoring for Harm – HIV Acquisition


Significance of potential case-splits at STOC interim safety analysis

| HIV infections | | P value ¹ |
|----------------|---------|----------------------|
| Vaccine | Placebo | |
| 17 | 8 | 0.05 |
| 18 | 7 | 0.03 |
| 19 | 6 | 0.007 |
| 20 | 5 | 0.002 |

¹ One-sided, exact binomial test


Correlates of Immunity

- ▶ Correlates of immunity can be explored, but with limited power
- ▶ Correlates should be assessed in subsequent trials once some level of efficacy demonstrated in STOC



Correlates of Immunity


Correlation between viral load set point and immune response variable (eg ELISPOT) in STOC trial with 15 infected vaccinees ($r=-0.85$)



► The immune response explains 72% of the variation in log₁₀ VL

Heterogeneity

- ▶ Heterogeneity can decrease ability to assess VEs and VE_p
 - Known predictors of increased acquisition risk
 - ▶ Route of transmission
 - ▶ Gender
 - ▶ Circumcision status
 - ▶ HSV-2 infection
 - Vector serostatus
 - Circulating virus
 - Immune response



Heterogeneity

- ▶ STOC could select more homogeneous populations
 - single mode of transmission
 - same region or dominant subtype
 - same vector serostatus
 - same male circumcision status

- ▶ Smaller mechanism to test concepts
- ▶ Limited conclusions but fewer expectations

Conclusions

- ▶ Most candidates will fail → STOC is a means to minimize harm and maximize resources
- ▶ Screening for efficacy should be our initial goal
- ▶ STOC can assess harm and explore correlates of immunity
- ▶ Several STOC trials may be better than one larger heterogeneous trial



Acknowledgements

Wasima Rida, Biostatistics consultant

IAVI

- ▶ Pat Fast
- ▶ Jean-Louis Excler
- ▶ Wayne Koff

UNAIDS and Global HIV Vaccine Enterprise (sponsors of
UNAIDS/IAVI/WHO Consensus meeting on Phase IIB TOC)

Collaborating investigators

Study volunteers

IAVI Gratefully Acknowledges the Support of our Donors



IAVI gratefully acknowledges the generous support provided by the following major donors.*



Provided with the support of the European Union



EUIKO INHABILITATZA
GUBIERNU BASCO



Canadian International Development Agency

Agence Canadienne de développement international



Irish Aid
Government of Ireland
Rialtas na hÉireann



Buitenlandse Zaken



NORWEGIAN MINISTRY OF FOREIGN AFFAIRS

Alfred P. Sloan Foundation
Basque Autonomous Government
Becton, Dickinson and Company (BD)
Bill & Melinda Gates Foundation
Bristol-Myers Squibb (BMS)
Broadway Cares/Equity Fights AIDS
Canadian International Development Agency
Continental Airlines
European Union
Foundation for the National Institutes of Health
Google Inc.
The Haas Trusts
Henry Schein, Inc.
Irish Aid
James B. Pendleton Charitable Trust
The John D. Evans Foundation
Kathy Bole & Paul Klingenstein
Merck & Co., Inc.

Ministry of Foreign Affairs and Cooperation, Spain
Ministry of Foreign Affairs of Denmark
Ministry of Foreign Affairs of The Netherlands
Ministry of Foreign Affairs of Sweden
The New York Community Trust
Norwegian Royal Ministry of Foreign Affairs
Pfizer Inc
The Rockefeller Foundation
Swedish International Development Cooperation Agency
U.K. Department for International Development
Until There's a Cure Foundation
The U.S. President's Emergency Plan for AIDS Relief through the U.S. Agency for International Development
The William and Flora Hewlett Foundation
The World Bank through its Development Grant Facility

* As of 04/08

And many other generous individuals from around the world.



USAID
FROM THE AMERICAN PEOPLE



THE WORLD BANK



DFID Department for International Development



Ministry for Foreign Affairs Sweden





IMAGINE a World Without AIDS

